These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 14627056)
1. Task Force report of the Patient-Reported Outcomes Harmonization Group: too much harmony, not enough melody? Lenderking W Value Health; 2003; 6(5):503-4. PubMed ID: 14627056 [No Abstract] [Full Text] [Related]
2. Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001. Acquadro C; Berzon R; Dubois D; Leidy NK; Marquis P; Revicki D; Rothman M; Value Health; 2003; 6(5):522-31. PubMed ID: 14627058 [TBL] [Abstract][Full Text] [Related]
3. Beyond the FDA PRO guidance: steps toward integrating meaningful patient-reported outcomes into regulatory trials and US drug labels. Basch E Value Health; 2012 May; 15(3):401-3. PubMed ID: 22583448 [No Abstract] [Full Text] [Related]
4. Academy of Managed Care Pharmacy Format: relevance, rigor, regulation, and realism. O'Brien BJ Value Health; 2003; 6(5):501-2. PubMed ID: 14627055 [No Abstract] [Full Text] [Related]
5. Comments on the ISPOR Task Force Report on Translation and Adaptation of Outcomes Measures: guidelines and the need for more research. Lenderking WR Value Health; 2005; 8(2):92-3. PubMed ID: 15804317 [No Abstract] [Full Text] [Related]
7. The Academy of Managed Care Pharmacy Format for Formulary Submissions: an evolving standard--a Foundation for Managed Care Pharmacy Task Force report. Fry RN; Avey SG; Sullivan SD Value Health; 2003; 6(5):505-21. PubMed ID: 14627057 [TBL] [Abstract][Full Text] [Related]
8. How a well-grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure. Brozek JL; Guyatt GH; Schünemann HJ Health Qual Life Outcomes; 2006 Sep; 4():69. PubMed ID: 17005037 [TBL] [Abstract][Full Text] [Related]
9. Changing end points in breast-cancer drug approval--the Avastin story. D'Agostino RB N Engl J Med; 2011 Jul; 365(2):e2. PubMed ID: 21707384 [No Abstract] [Full Text] [Related]
10. The academic research consortium governance charter. Krucoff MW; Mehran R; van Es GA; Boam AB; Cutlip DE JACC Cardiovasc Interv; 2011 May; 4(5):595-6. PubMed ID: 21596341 [No Abstract] [Full Text] [Related]
11. Financial conflicts of interest in biomedical human subject research. Goldstein N J Biolaw Bus; 2006; 9(1):26-37. PubMed ID: 17111525 [TBL] [Abstract][Full Text] [Related]
12. FDA to clarify rules on advisory committee members. Tanne JH BMJ; 2006 Aug; 333(7562):278. PubMed ID: 16888304 [No Abstract] [Full Text] [Related]
13. Review of the Task Force Report on PRO data collection in clinical trials using mixed modes. McLeod L Value Health; 2014 Jul; 17(5):491-2. PubMed ID: 25128040 [No Abstract] [Full Text] [Related]
14. Investigator, IRB and institutional financial conflicts in interest in human-subject research: past, present and future. Barnes M; Florencio PS Seton Hall Law Rev; 2003; 32(3):525-60. PubMed ID: 12741411 [No Abstract] [Full Text] [Related]
15. Light, fast, and flexible: a new approach to regulation of human gene therapy. Cregan JA McGeorge Law Rev; 2000; 32(1):261-87. PubMed ID: 15709266 [No Abstract] [Full Text] [Related]
16. Practice advisory for preanesthesia evaluation: an updated report by the American Society of Anesthesiologists Task Force on Preanesthesia Evaluation. ; Apfelbaum JL; Connis RT; Nickinovich DG; ; Pasternak LR; Arens JF; Caplan RA; Connis RT; Fleisher LA; Flowerdew R; Gold BS; Mayhew JF; Nickinovich DG; Rice LJ; Roizen MF; Twersky RS Anesthesiology; 2012 Mar; 116(3):522-38. PubMed ID: 22273990 [No Abstract] [Full Text] [Related]
17. A competency-based approach to expanding the cancer care workforce. Smith AP; Lichtveld MY Medsurg Nurs; 2007 Apr; 16(2):109-17; quiz 118. PubMed ID: 17547269 [No Abstract] [Full Text] [Related]
18. How experts are chosen to inform public policy: can the process be improved? Rowe S; Alexander N; Weaver CM; Dwyer JT; Drew C; Applebaum RS; Atkinson S; Clydesdale FM; Hentges E; Higley NA; Westring ME; Health Policy; 2013 Oct; 112(3):172-8. PubMed ID: 23415508 [TBL] [Abstract][Full Text] [Related]
19. Uneasy alliance--clinical investigators and the pharmaceutical industry. Bodenheimer T N Engl J Med; 2000 May; 342(20):1539-44. PubMed ID: 10816196 [No Abstract] [Full Text] [Related]
20. FTC and DOJ jointly propose antitrust guidelines for collaborations among competitors. Chefitz JG; Martin LK; Sullivan LC Health Care Law Mon; 1999 Nov; ():3-7. PubMed ID: 11067432 [No Abstract] [Full Text] [Related] [Next] [New Search]